A case of urticarial vasculitis associated with atezolizumab

A case of urticarial vasculitis associated with atezolizumab

Bibliographic Details
Main Authors:	Jade N. Young, BS, Ryan Rivera-Oyola, MD, Dina Poplausky, BA, Yamato Suemitsu, MD, Randie H. Kim, MD, PhD, Deborah Doroshow, MD, PhD, Nicholas Gulati, MD, PhD
Format:	Article
Language:	English
Published:	Elsevier 2024-01-01
Series:	JAAD Case Reports
Subjects:	atezolizumab cirAE cutaneous immune-related adverse event immune checkpoint inhibitor immune-related adverse event irAE
Online Access:	http://www.sciencedirect.com/science/article/pii/S2352512623004228

Similar Items

The use of biologic medications for the treatment of cutaneous immune-related adverse events secondary to immune checkpoint inhibitors: A single-institution real-life study
by: Jade N. Young, BS, et al.
Published: (2024-01-01)

Atezolizumab-induced bilateral anterior uveitis: A case report
by: Tsuyoshi Mito, et al.
Published: (2021-12-01)

Atezolizumab-Induced Aseptic Meningitis in Patients with NSCLC
by: Ryo Toyozawa, MD, et al.
Published: (2020-03-01)

Rapidly progressing dyspnea and retiform purpura
by: Bianca Y. Kang, MD, et al.
Published: (2022-12-01)

Non-Invasive Predictive Biomarkers for Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors
by: Ben Ponvilawan, et al.
Published: (2024-03-01)

Meta‐analysis of immune‐related adverse events of immune checkpoint inhibitor therapy in cancer patients
by: Peng Song, et al.
Published: (2020-09-01)

Insights into Potential Pathogenesis and Treatment Options for Immune-Checkpoint Inhibitor-Related Pneumonitis
by: Hiroyuki Ando, et al.
Published: (2021-10-01)

The Timing, Trajectory, and Incidence of Immune-Related Adverse Events in NSCLC Treated With Atezolizumab
by: Katherine E.R. Smith, MD, et al.
Published: (2023-12-01)

Immune Thrombocytopenia Induced by Immune Checkpoint Inhibitrs in Lung Cancer: Case Report and Literature Review
by: Wang Xie, et al.
Published: (2021-12-01)

Challenges and Limitations of Endocrine Toxicity Evaluation in Non-Small Cell Lung Cancer Patients Treated with Immunotherapy—Retrospective Study from a Tertiary-Level Hospital in Romania
by: Simona Coniac, et al.
Published: (2023-05-01)

Management of immune checkpoint inhibitor‐related dermatologic adverse events
by: Xiaoyan Si, et al.
Published: (2020-02-01)

Investigating the Impact of Immune-Related Adverse Events, Glucocorticoid Use and Immunotherapy Interruption on Long-Term Survival Outcomes
by: Charline Lafayolle de la Bruyère, et al.
Published: (2021-05-01)

External validation of biomarkers for immune-related adverse events after immune checkpoint inhibition
by: Gunther Glehr, et al.
Published: (2022-09-01)

Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy
by: Vivek Kumar, et al.
Published: (2017-02-01)

Hypothyroidism as an immune-related adverse event caused by atezolizumab in a patient with muscle spasms: a case report
by: Masanori Kawataki, et al.
Published: (2022-01-01)

Pharmacological Treatments Available for Immune-Checkpoint-Inhibitor-Induced Colitis
by: Sae Ohwada, et al.
Published: (2022-06-01)

Multi-organ Immune-Related Adverse Event Is a Risk Factor of Immune Checkpoint Inhibitor-Associated Myocarditis in Cancer Patients: A Multi-center Study
by: Xiaohong Xie, et al.
Published: (2022-07-01)

Predictive Biomarkers of Severe Immune-Related Adverse Events With Immune Checkpoint Inhibitors: Prevention, Underlying Causes, Intensity, and Consequences
by: Ana Cardeña-Gutiérrez, et al.
Published: (2022-06-01)

Clinical diagnosis and treatment recommendations for ocular toxicities of targeted therapy and immune checkpoint inhibitor therapy
by: Xiaowei Liu, et al.
Published: (2020-03-01)

Immune checkpoint inhibitor-induced myocarditis and myositis in liver cancer patients: A case report and literature review
by: Haoran Mei, et al.
Published: (2023-01-01)

Highly variable timing renders immunotherapy efficacy and toxicity impractical biomarkers of one another in clinical practice
by: Mitchell S. von Itzstein, et al.
Published: (2024-04-01)

Imaging Findings in Patients with Immune Checkpoint Inhibitor-Induced Arthritis
by: Andrés Ponce, et al.
Published: (2022-08-01)

Tissue-resident memory T cells in immune-related adverse events: friend or foe?
by: Robin Reschke, et al.
Published: (2023-12-01)

Anti-PD-1 immune-related adverse events are associated with high therapeutic antibody fixation on T cells
by: Marianne Gazzano, et al.
Published: (2022-12-01)

Temporary Severe Neutropenia during Administration of Atezolizumab: A Novel Case Report
by: Ryota Kanno, et al.
Published: (2023-05-01)

Editorial: Immune-related adverse events for patients with lung cancer-volume II
by: Yusha Wang, et al.
Published: (2023-11-01)

Clinical characteristics and treatment efficacy of immune checkpoint inhibitors (ICIs) in patients with ICIs-induced Adrenal insufficiency
by: Jing Xiang, et al.
Published: (2023-12-01)

Immune-related adverse effects of checkpoint immunotherapy and implications for the treatment of patients with cancer and autoimmune diseases
by: Betul Ibis, et al.
Published: (2023-06-01)

A case of subclinical immune checkpoint inhibitor-associated myocarditis in non-small cell lung cancer
by: Yue Hu, et al.
Published: (2023-04-01)

Cardiotoxicity induced by immune checkpoint inhibitor: The complete insight into mechanisms, monitoring, diagnosis, and treatment
by: Sridha Ganesh, et al.
Published: (2022-09-01)

Clinical course and management of insidious adrenal crisis manifested initially as hyperpyrexia secondary to pembrolizumab: Case reports and literature review
by: Dandan Geng, et al.
Published: (2022-08-01)

Overview of Checkpoint Inhibitors Mechanism of Action: Role of Immune-Related Adverse Events and Their Treatment on Progression of Underlying Cancer
by: Patricia Iranzo, et al.
Published: (2022-05-01)

Pembrolizumab-Induced Immune-Mediated Colitis in a Patient with Concurrent Clostridium Difficile Infection
by: Cheng Zhou, et al.
Published: (2019-02-01)

A case of simultaneous occurrence of hepatitis and pancreatitis during the combination immunochemotherapy for non-small cell lung carcinoma
by: Satoshi Tanaka, et al.
Published: (2020-01-01)

Hematological Side Effects of Immune Checkpoint Inhibitors: The Example of Immune-Related Thrombocytopenia
by: Roser Calvo
Published: (2019-04-01)

Case Report: Peripheral blood T cells and inflammatory molecules in lung cancer patients with immune checkpoint inhibitor-induced thyroid dysfunction: Case studies and literature review
by: Mona A. Marie, et al.
Published: (2022-12-01)

Immune Checkpoint Inhibitor-Related Myositis Overlapping With Myocarditis: An Institutional Case Series and a Systematic Review of Literature
by: Yuki Nakagomi, et al.
Published: (2022-05-01)

Application of artificial liver in immune-related liver injury induced by immune checkpoint inhibitor: Case reports and review of the literature
by: Xuewei Li, et al.
Published: (2022-09-01)

Adrenal crisis mainly manifested as recurrent syncope secondary to tislelizumab: a case report and literature review
by: Haishan Wei, et al.
Published: (2024-01-01)

Association between Immune Related Adverse Events and Outcome in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors
by: Agnese Paderi, et al.
Published: (2021-02-01)